The FDA has recently approved a new drug called nintedanib for a form of lung scarring and researchers have now begun to test the drug as a possible therapy in the treatment of mesothelioma.
The drug blocks several pathways that may be involved in the scarring of lung tissue and is to be used for those with idiopathic pulmonary fibrosis (IPF) which is both a serious and chronic condition with symptoms identical to the asbestos related condition asbestosis. In the same way as those with mesothelioma, there are few viable treatment options.
However, in clinical trials of 1,231 patients with IPF, nintedanib improved the amount of air patients could exhale after a deep breath. It is now being tested as an anti-cancer drug for mesothelioma and other cancers.
The mesothelioma trial is open to patients with the disease who have not had chemotherapy or radiotherapy and who are expected to live for at least three months San Francisco is one of the locations included in the trial.
If you have been diagnosed with any an asbestos related disease, you may be entitled to monetary compensation. To find out how we can help you recover for your asbestos related claim, contact the Law Office of Brayton Purcell, LLP at (800) 598-0314 immediately, or contact us online for a free consultation.
